Clinical Evaluation of the Efficacy OF Botulinum Toxin A for Improving Facial Scars
Status:
Active, not recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
Background: Scars widen when the overlying musculature pulls apart suture lines. Because
Botulinum Toxin A (BTA) is known to prevent fibroblast proliferation and it also induces
temporary muscle paralysis, the purpose of this current study is to evaluate the beneficial
effects of Botulinum toxin type A (BTA) on scar formation.
Aim of this study: The aim of this study is to evaluate the efficacy and safety of early
postoperative Botulinum Toxin type A (BTA) injection on improving vertical or oblique facial
surgical scars.
Materials and methods: Patients with vertical or oblique forehead lacerations, treated by
primary closure, will be enrolled in this study and randomized into two groups: One group (n
=6) will receive BTA injection within 5 days of primary closure and the other group (n = 6)
will receive no further treatment. Vancouver scar scale (VSS) Scores and wound width will be
determined at the 1, 3 and 6 months follow-up visits, along with clinical photographs.
Results: Data will be collected, tabulated and statically analyzed. Key words: Botulinum
Toxin Type A; facial scarring; wound healing; scar maturation